대한뉴팜

[Notice] Results of the 2006 Drug Reevaluation In accordance with Article 26-3 and Article 34, Paragraph 4 of the Pharmaceutical Affairs Act and the [Regulations on the Implementation of Drug Reevaluation (KFDA Notification)], a reevaluation was conducted for 636 products across 13 therapeutic classes for blood and body fluids. The results are hereby announced. *** See relevant products below *** Silotal Tab (Cilostazol) [link]Tramin Injection 250 mg (Tranexamic Acid)Tramin Injection 500 mgHerin Injection (Heparin Sodium) For inquiries regarding this notice:Responsible Department: Daehan New Pharm R&D DivisionContact: 02-3415-7857

Daehan New Pharm Co., Ltd. (CEO: Park Myung-rae) held its 22nd anniversary ceremony on the 20th in the main auditorium of the headquarters with executives and employees in attendance. During the event, an awards ceremony was held to congratulate and encourage those involved and employees who contributed to the company's development with five employees recognized for 20 and 10 years of long service. In his commemorative speech, CEO Park Myung-rae said, "As we enter the era of youth, let us create a stable profit structure through infinite challenge and continuous effort, and achieve sustainable growth." He presented detailed guidelines for successful development, emphasizing: "First, securing competitiveness by strengthening core competencies in each business division. Second, creating a young and strong company that leads all tasks with passion and audacity. Third, expanding an advanced system to respond swiftly to change. Fourth, constant self-development to cultivate expertise. Finally, open-mindedness among members." He also urged the ceremony to be an occasion for executives and employees to raise their competitiveness to the highest level and commit to a fresh leap forward. At the ceremony, Mr. Kim Ja-seop, staff of the Animal Production Department, received a commendation and a prize of 20 don of gold for 20 years of service. Executive Director Son Young-wook and three others in the Animal Health Business Headquarters received 10-year service awards and a prize of 10 don of gold. In addition, 15 outstanding employees were awarded overseas training in Southeast Asia as a prize.

ATAT 2006 Event Held; Commitment to P-3 Implementation From the 7th to the 8th, a two-day experiential team-building POST training titled “Achieving Target All Together (ATAT) 2006” was conducted for all employees to enhance organizational cohesion under the slogan “Let’s Achieve Our Goals Together.” The training held on the 7th at Daegwallyeong Ranch in Hoenggye-gun, Gangwon Province, consisted of a four-stage POST teamwork program aimed at uniting all members, self-contract training to boost confidence and success awareness, and creative problem-solving exercises encouraging teams to solve assigned problems innovatively. Participants pledged to take the lead in change and actively carry out their duties with renewed determination. Based on the slogan “Let’s Achieve Our Goals Together,” the detailed implementation goals of ‘P-3 (Perfect Sale, Perfect Product, Perfect Management)’ were set to strengthen momentum and unity for achieving company objectives. Additionally, a special lecture on “Professionalism” was delivered by Lim Im-taek, a visually impaired full-time instructor at Canaan Farmer School and a featured speaker on MBC’s ‘Exclamation Mark-Street Lecture.’ He shared insights on realizing goals, continuous self-development for a life without regrets, and the true meaning and value of passion in one’s work and profession. The company plans to continue organizing various sports and cultural events involving all employees to foster a new corporate culture.

Notice of Change Instructions for Approval Details (Precautions for Use) Regarding Glibenclamide Single Ingredient and Others In accordance with the Pharmaceutical Safety Information Management Regulations (KFDA Notification No. 2004-30, dated April 27, 2004), we hereby inform you that change instructions (Pharmaceutical Management Team-13476) have been made to the approval details (precautions for use) of Glibenclamide single ingredient and related products as follows. Ecnic Cream (Hydroquinone) For inquiries regarding this notice: Responsible Department: Daehan New Pharm Development Division Contact Number: 02-3415-7857

- Promotion List - △ Senior Managing Director: Head of Pharmaceutical Business Division, Kim Kyung-hoon△ Director: Production Division, Oh In-ok△ Deputy General Manager: Sales Planning & Management Department, Kang Deok-young; OTC Business Department, Lee Sang-pil△ Assistant General Manager: Production Support Department, Yoon Young-sun△ Deputy Assistant General Manager: Quality Control Department, Choi Kyung-hoon△ Manager: Animal Drug Sales Department, Oh Sung-hyun; Academic Development Department, Jang Young-jin; Quality Control Department, Won Hoo-jae; Animal Drug Development & Marketing Department, Kim Jong-man; Animal Drug Production Department, Choi Woon-chul△ Assistant Manager: Quality Control Department, Park Jun-ho; ETC Business Department, Kim Dae-hyun; Production Support Department, Kim Jae-hyuk; ETC Business Department, Lee Hyung-jin, Han Hong-taek, Seo Kang-seok, Kang Hyung-min, Yoon Tae-won△ Senior Staff: Animal Drug Sales Department, Kim Kwan-hee, Lim Sung-jin; ETC Business Department, Choi Woo-young; Marketing Department, Jo Soo-jin; General Affairs & Personnel Department, Yoo Sang-min; Sales Planning & Management Department, Choi Eun-yeol; ETC Business Department, Song Shin-ho; Academic Development Department, Kim Dong-geun△ Promotion: Animal Drug Production Department, Kwon Min-sun; Production Support Department, Kim Tae-woo; Pharmaceutical Production Department, Ahn Sung-woo, Park Soon-ok

[Notice] Instructions for Changes to Approval Details (Precautions for Use) of Non-Steroidal Anti-Inflammatory DrugsIn accordance with the Pharmaceutical Safety Information Management Regulations (KFDA Notification No. 2004-30, April 27, 2004), the following changes have been made regarding the approval details (precautions for use) of non-steroidal anti-inflammatory drugs (Pharmaceutical Management Team-1246). Products impacted:Nimax Tablets (Nimesulide)Cnac Injection (Diclofenac Beta-Dimethylamino Ethanol)Taruming Tablets (Tarniflumate)Roxpine Tablets (Roxoprofen Sodium)For inquiries related to this notice:Responsible Department: Daehan New Pharm Development DivisionContact: 02-3415-7857

In accordance with Article 26-3 and Article 34, Paragraph 4 of the Pharmaceutical Affairs Act and the [Regulations on the Implementation of Drug Reevaluation (KFDA Notification)], a reevaluation was conducted for [7 vitamin therapeutic groups, 367 products] and [7 tonic therapeutic groups, 900 products] with results hereby announced. Affected products include:Placein M Injection (Human Placenta Extract)Calibin Soft Capsules (Calcitriol)For inquiries regarding this notice: Responsible Department: Daehan New Pharm R&D Division Contact: 02-3415-7857

Daehan New Pharm Co., Ltd. Launches "Citracal F/D Tablets"Improved Calcium Bioavailability... Minimizes Side Effects Such as Gastrointestinal Disorders Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) has released ETC-type "Citracal F Tablets" and OTC-type "Citracal D Tablets," calcium supplements combining calcium citrate and vitamin D3. Citracal F/D Tablets, combining calcium citrate and vitamin D3, have improved absorption rate and calcium bioavailability by over 30% compared to conventional calcium carbonate or oyster shell powder. Unlike calcium carbonate supplements, they do not produce gas in the intestines, minimizing side effects such as gastrointestinal discomfort, constipation, and kidney stone formation. Particularly, Citracal F Tablets are covered by insurance and improve patient adherence with a once-daily dosage. Daehan New Pharm Co., Ltd. aims to expand sales by dual marketing strategies using Citracal F Tablets for ETC prescriptions and Citracal D Tablets for OTC pharmacy sales.

Daehan New Pharm Holds Opening Ceremony and New Product Launch Ceremony Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) held its opening ceremony and new product launch on January 2-3 at the Rabidol Resort with all employees in attendance under the slogan “Healthy Life, Disease-Free Society, A Company Sharing Warmth.” During the opening ceremony, New Year’s greetings were exchanged and awards were presented to seven exemplary employees. CEO Park Myung-rae, in his New Year’s speech, praised the employees for achieving last year’s sales target of 50 billion KRW and emphasized three key focus areas for leap-forward development as a top-tier pharmaceutical company: continuous management innovation, sharing awareness and voluntary participation among members, and creating added value individually. Following the opening ceremony, the new product launch featured Citracal F Tablets (ETC) and D Tablets (OTC), which enhance bioavailability by over 30% compared to existing calcium supplements while significantly reducing side effects. The entire staff renewed their commitment to the successful launch and growth of these key products. A special lecture on “Time Management” was delivered by Dr. Song Hyuk-kwan, director of the Paradigm Research Institute, reinforcing efficient work management. Later, Mr. Lee Sang-yong, known for his social service efforts including heart surgery for children, spoke about the social responsibility of pharmaceutical companies, inspiring attendees to reflect on the company’s role in society.